Literature DB >> 21861620

Ocular herpes simplex virus: how are latency, reactivation, recurrent disease and therapy interrelated?

Lena J Al-Dujaili1, Patrick P Clerkin, Christian Clement, Harris E McFerrin, Partha S Bhattacharjee, Emily D Varnell, Herbert E Kaufman, James M Hill.   

Abstract

Most humans are infected with herpes simplex virus (HSV) type 1 in early childhood and remain latently infected throughout life. While most individuals have mild or no symptoms, some will develop destructive HSV keratitis. Ocular infection with HSV-1 and its associated sequelae account for the majority of corneal blindness in industrialized nations. Neuronal latency in the peripheral ganglia is established when transcription of the viral genome is repressed (silenced) except for the latency-associated transcripts and microRNAs. The functions of latency-associated transcripts have been investigated since 1987. Roles have been suggested relating to reactivation, establishment of latency, neuronal protection, antiapoptosis, apoptosis, virulence and asymptomatic shedding. Here, we review HSV-1 latent infections, reactivation, recurrent disease and antiviral therapies for the ocular HSV diseases.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21861620      PMCID: PMC3403814          DOI: 10.2217/fmb.11.73

Source DB:  PubMed          Journal:  Future Microbiol        ISSN: 1746-0913            Impact factor:   3.165


  275 in total

1.  Binding of the herpes simplex virus immediate-early gene product ICP4 to its own transcription start site.

Authors:  M T Muller
Journal:  J Virol       Date:  1987-03       Impact factor: 5.103

2.  Trends in herpes simplex virus type 1 and type 2 seroprevalence in the United States.

Authors:  Fujie Xu; Maya R Sternberg; Benny J Kottiri; Geraldine M McQuillan; Francis K Lee; Andre J Nahmias; Stuart M Berman; Lauri E Markowitz
Journal:  JAMA       Date:  2006-08-23       Impact factor: 56.272

3.  Herpes simplex virus latent phase transcription facilitates in vivo reactivation.

Authors:  J M Hill; F Sedarati; R T Javier; E K Wagner; J G Stevens
Journal:  Virology       Date:  1990-01       Impact factor: 3.616

Review 4.  A triple entente: virus, neurons, and CD8+ T cells maintain HSV-1 latency.

Authors:  Sherrie Divito; Thomas L Cherpes; Robert L Hendricks
Journal:  Immunol Res       Date:  2006       Impact factor: 2.829

5.  Resistance to HSV-1 in the mouse is governed by two major, independently segregating, non-H-2 loci.

Authors:  C Lopez
Journal:  Immunogenetics       Date:  1980-07       Impact factor: 2.846

6.  ICP4, the major transcriptional regulatory protein of herpes simplex virus type 1, forms a tripartite complex with TATA-binding protein and TFIIB.

Authors:  C A Smith; P Bates; R Rivera-Gonzalez; B Gu; N A DeLuca
Journal:  J Virol       Date:  1993-08       Impact factor: 5.103

7.  Risk factors for corneal graft failure and rejection in the collaborative corneal transplantation studies. Collaborative Corneal Transplantation Studies Research Group.

Authors:  M G Maguire; W J Stark; J D Gottsch; R D Stulting; A Sugar; N E Fink; A Schwartz
Journal:  Ophthalmology       Date:  1994-09       Impact factor: 12.079

8.  Regulation of caspase 8- and caspase 9-induced apoptosis by the herpes simplex virus type 1 latency-associated transcript.

Authors:  Gail Henderson; Weiping Peng; Ling Jin; Guey-Chuen Perng; Anthony B Nesburn; Steven L Wechsler; Clinton Jones
Journal:  J Neurovirol       Date:  2002-12       Impact factor: 2.643

9.  The effect of HSV multiplication rate on antiviral drug efficacy in vitro.

Authors:  J M Upadhyay; J M Hill; M Jemison; M F Helmy; H E Kaufman
Journal:  Antiviral Res       Date:  1991-01       Impact factor: 5.970

10.  Efficacy of valacyclovir vs acyclovir for the prevention of recurrent herpes simplex virus eye disease: a pilot study.

Authors:  Elisabetta Miserocchi; Giulio Modorati; Laura Galli; Paolo Rama
Journal:  Am J Ophthalmol       Date:  2007-08-09       Impact factor: 5.258

View more
  37 in total

1.  Modulation of reactivation of latent herpes simplex virus 1 in ganglionic organ cultures by p300/CBP and STAT3.

Authors:  Te Du; Guoying Zhou; Bernard Roizman
Journal:  Proc Natl Acad Sci U S A       Date:  2013-06-20       Impact factor: 11.205

2.  HSV carrying WT REST establishes latency but reactivates only if the synthesis of REST is suppressed.

Authors:  Guoying Zhou; Te Du; Bernard Roizman
Journal:  Proc Natl Acad Sci U S A       Date:  2013-01-22       Impact factor: 11.205

3.  Novel biotinylated lipid prodrugs of acyclovir for the treatment of herpetic keratitis (HK): transporter recognition, tissue stability and antiviral activity.

Authors:  Aswani Dutt Vadlapudi; Ramya Krishna Vadlapatla; Ravinder Earla; Suman Sirimulla; Jake Brain Bailey; Dhananjay Pal; Ashim K Mitra
Journal:  Pharm Res       Date:  2013-05-09       Impact factor: 4.200

Review 4.  Ocular surgery after herpes simplex and herpes zoster keratitis.

Authors:  Piotr Kanclerz; Jorge L Alio
Journal:  Int Ophthalmol       Date:  2020-09-10       Impact factor: 2.031

5.  The Current State of Vaccine Development for Ocular HSV-1 Infection.

Authors:  D J Royer; A Cohen; Djj Carr
Journal:  Expert Rev Ophthalmol       Date:  2015-04-01

6.  Serine/Arginine-rich Splicing Factor 2 Modulates Herpes Simplex Virus Type 1 Replication via Regulating Viral Gene Transcriptional Activity and Pre-mRNA Splicing.

Authors:  Ziqiang Wang; Qing Liu; Jinhua Lu; Ping Fan; Weidong Xie; Wei Qiu; Fan Wang; Guangnan Hu; Yaou Zhang
Journal:  J Biol Chem       Date:  2016-10-26       Impact factor: 5.157

7.  Delivery of herpes simplex virus to retinal ganglion cell axon is dependent on viral protein Us9.

Authors:  Jolene M Draper; Guiqing Huang; Graham S Stephenson; Andrea S Bertke; Daniel A Cortez; Jennifer H LaVail
Journal:  Invest Ophthalmol Vis Sci       Date:  2013-02-01       Impact factor: 4.799

Review 8.  Intracerebral propagation of Alzheimer's disease: strengthening evidence of a herpes simplex virus etiology.

Authors:  Melvyn J Ball; Walter J Lukiw; Eli M Kammerman; James M Hill
Journal:  Alzheimers Dement       Date:  2012-11-14       Impact factor: 21.566

Review 9.  Glycoprotein targeted therapeutics: a new era of anti-herpes simplex virus-1 therapeutics.

Authors:  Thessicar E Antoine; Paul J Park; Deepak Shukla
Journal:  Rev Med Virol       Date:  2013-02-26       Impact factor: 6.989

10.  The HIV Integrase Inhibitor Raltegravir Inhibits Felid Alphaherpesvirus 1 Replication by Targeting both DNA Replication and Late Gene Expression.

Authors:  Matthew R Pennington; Ian E H Voorhees; Heather M Callaway; Shannon D Dehghanpir; Joel D Baines; Colin R Parrish; Gerlinde R Van de Walle
Journal:  J Virol       Date:  2018-09-26       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.